Jeff Aronin, Deepening the Possibilities of Medical Research

Based in Chicago, Illinois, Paragon Bioscience invests in biopharmaceutical companies and it develops incubators for organizations dedicated to scientific and medical research. In the last ten years, Paragon Biosciences has received approval from the Food and Drug Administration (FDA) for 13 new medications. Drugs that have drastically improved patients’ outcomes for conditions such as premalignant oral lesions, vitiligo, atopic dermatitis and central nervous system disorder. Bringing these medications to market was due to groundbreaking research by the companies developed and created by Paragon, these include Castle Creek Pharma, Decade Pharmaceuticals and Harmony Biosciences and Precision BP (http://alivenewspaper.com/2018/02/jeff-aronin-paragon-biosciences/).

As contributors to the medical field, the companies can be divided into two categories, Castle Creek and Decade are biopharmaceuticals and Harmony and Precision are scientific research and development organizations. As a business Paragon Bioscience goes beyond being an incubator and investor for new companies; they also participate in philanthropic giving in areas involving community interests, education, advanced science and disease states. Paragon Bioscience is furthering cures for specific conditions by merging scientific research with medical innovation.

The head of Paragon Bioscience’s organizational structure is the chief executive officer (CEO) and chairman, Jeff Aronin (Jeffaronin). Named to the top management position in 2010, Jeff has been instrumental in the development of Paragon as a standout organization in the field of biopharmaceutical investing. When a new drug is discovered through scientific research, it then moves into a pre-clinical testing phase and that’s followed by three phases of registration and enrolling study participants for clinical trials. Aronin oversees the critical stage of finding talented scientists for the discovery phase and he also hires teams of executives for other positions.

With 20 years of experience, Jeff Aronin continues leading Paragon Bioscience into the future by finding smart opportunities to invest in. They play a critical role in corporate acquisitions and merger and as an incubator for developing new promising businesses. Paragon employs different investment strategies for outcomes that are patient focused and managed by the organization. Paragon Bioscience uses the scientific reality of pharmaceutical research to develop new and innovative medications. Medications that have high potential for treating patients in ways not explored before.